Crescent Biopharma
CBIO
50 hedge funds and large institutions have $115M invested in Crescent Biopharma in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 7 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
4% more funds holding
Funds holding: 48 → 50 (+2)
0.82% more ownership
Funds ownership: 0% → 0.82% (+0.82%)
12% less capital invested
Capital invested by funds: $132M → $115M (-$16.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.5M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$475K |
| 3 |
Millennium Management
New York
|
+$317K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$231K |
| 5 |
Morgan Stanley
New York
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$925K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$175K |
| 3 |
Renaissance Technologies
New York
|
-$101K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$99K |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
-$84.2K |
CBIO Hedge Fund Activity: Q4 2016 in Review
50 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2016, worth a combined $115M — down 12% from $132M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CBIO positions and 7 closed out — a net gain of 3 holders — while 17 added to existing stakes and 7 trimmed.
The largest buyer was BVF Inc, adding an estimated $2.5M. The largest seller was Invesco, exiting entirely with an estimated $925K sold.
- 50 institutional investors held Crescent Biopharma (CBIO) as of Q4 2016, up from 48 in Q3 2016.
- Funds reported $115M of Crescent Biopharma stock for Q4 2016, down 12% quarter-over-quarter.
- 10 funds opened new Crescent Biopharma positions in Q4 2016 and 7 closed out, a net change of +3 holders.
- The largest Crescent Biopharma buyer in Q4 2016 was BVF Inc, an estimated $2.5M added.
- The largest Crescent Biopharma seller in Q4 2016 was Invesco, an estimated $925K sold.
Based on aggregated 13F filings for Q4 2016.